The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Abstract
Key Points: High levels of the anti-apoptotic factor BCL-2 can be therapeutically exploited by the BH3 mimetic ABT-199 in human T-ALL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, ABT-199 caused less damage to platelets than the second-generation drug ABT-263 in both in vitro and in vivo studies.362–364”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [362]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Cited by
Sorted by citations
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.63 · Cited by 460
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Jain, N., Lamb, A. V., O'Brien, S. M., Ravandi, F., Konopleva, M. Y., Jabbour, E. J., Zuo, Z., Jorgensen, J. L., Lin, P., Pierce, S. A., et al. (2016) · Blood · doi:10.1182/blood-2015-08-661702 · Cited by 354
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 289
Frismantas, V., Dobay, M. P., Rinaldi, A. M., Tchinda, J., Dunn, S. H., Kunz, J. B., Richter‐Pechańska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 266
Metadata
- Authors
- Peirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., Lammens, T., De Moerloose, B., Benoit, Y., Poppe, B., Meijerink, J. P., Cools, J., Soulier, J., Rabbitts, T. H., Taghon, T., Speleman, F., & Van Vlierberghe, P.
- Affiliations
- Center for Medical Genetics,
- Vlaams Instituut voor Biotechnologie (BE)
- Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium;
- John Radcliffe Hospital (GB)
- Laboratory for the Molecular Biology of Leukemia, Center for Human Genetics, University of Leuven and Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium;
- Erasmus MC (NL)
- Inserm (FR)
- Ghent University Hospital (BE)
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
- Ghent University (BE)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-12-11
- Volume
- 124
- Issue
- 25
- Pages
- 3738-3747
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2048591984
- Cited by
- 264
- References
- 44
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 31 · 2023: 29 · 2022: 24 · 2021: 25 · 2020: 22 · 2019: 25 · 2018: 22 · 2017: 18 · 2016: 22 · 2015: 16
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- European Hematology Association (TRTH104)
- Wellcome Trust (099246/Z/12/Z)
- Agence Nationale de la Recherche (ANR-10-IBHU-0002)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- venetoclax, BCL-2 inhibition, BH3 mimetics, T-cell acute lymphoblastic leukemia, drug synergy, doxorubicin, L-asparaginase, dexamethasone, TLX3, HOXA, TAL1, molecular subtypes, treatment resistance
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cells, Cultured, Child, Drug Synergism, Humans, Sulfonamides, Tumor Cells, Cultured, Blotting, Western, Gene Expression Regulation, Leukemic, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Bridged Bicyclo Compounds, Heterocyclic, Jurkat Cells, Proto-Oncogene Proteins c-bcl-2, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Xenograft Model Antitumor Assays, Cell Line, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
